Old Zantac claims: which cancers did the court list?

The federal court listed five cancer types for its evidence process. That list is not a diagnosis or proof of drug cause. It does not promise that a firm will take your case.

Which cancers did the federal order call designated?

It listed bladder, esophageal, gastric, liver and pancreatic cancers. These were groups for court work on expert proof. They were not proven drug injuries.

The February 2023 order describes expert reports supplied for those five types. Gastric means stomach cancer. The court category does not tell you which organ a cancer first arose in.

Did the federal court accept those cancer claims?

The later order says the court rejected expert proof for those five cancers in December 2022. The brands won the related request to end those claims.

General cause asks whether a substance can cause the disease, separate from what caused one person’s illness. This historical federal record does not certify the outcome of every later appeal or state case.

Were other cancers automatically covered?

No. The order sets a separate process for other cancers. Having a type outside the five groups does not mean the court will accept the proof.

Its requirements concern defined federal cases and parties. Those dated procedures are not a current intake rule or a new nationwide filing deadline. Ask which actual case and order apply.

Does a matching diagnosis show ranitidine caused it?

No. A cancer diagnosis identifies the disease. It does not, by itself, show that a medicine caused it.

NCI describes bladder cancer as uncontrolled growth in bladder cells, often starting in the lining. Knowing the site is important, but a matching disease name does not establish the product, exposure or legal proof.

Do the original user studies prove the whole list?

No. The studies differ. One found no clear overall rise; another found higher rates for several cancers. Neither proves every listed cancer or each person’s cause.

The positive findings are not proof for every listed cancer or person. Neither paper measured each user’s impurity dose. Unknown health factors, medicine use and follow-up limit what the comparisons can establish.

What should I ask about a state claim?

Ask which court, filed date and proof rules apply. Delaware’s April 2026 order ended a defined group of claims. It did not decide every national case.

It covers the consolidated complaints filed on or before December 1, 2025. Its separate discussion of later filings is not a promise of an available or successful route for you.